B7-H3 and its role in bone cancers |
| |
Authors: | Lile He Zhihong Li |
| |
Affiliation: | 1. Department of Orthopedics, The Second Xiangya Hospital, Central South University, Changsha, Hunan 410011, China;2. Department of Medical Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA |
| |
Abstract: | Most bone cancers have a high risk of metastasis, recurrence, and poor prognosis. Although conventional treatments are still the most important therapy, disadvantages still exist. Therefore, there is an unmet need to develop effective strategies. Immunotherapy is a promising therapy. Immunotherapies targeting checkpoints have proven to be successful, but B7-H3 (CD276, clusters of differentiation protein 276), a member of the B7-family of co-stimulatory molecules, is not being widely studied in bone cancers. This review summarized the studies on B7-H3 in bone cancers. 4 studies investigated B7-H3 expression in osteosarcoma, but there is no study on B7-H3 expression in chondrosarcoma. Two studies investigated the possibility to treat Ewing`s sarcoma through targeting the B7-H3 CAR (chimeric antigen receptors) T-cells or using anti-B7-H3 antibody. A study observed the growth of myeloma in B7-H3-deficient mice and the therapeutic effect of B7-H3 antibody and a study invested B7-H3 expression in myeloma patients. One study reported B7-H3 expression in osteoclastomas and one study investigated B7-H3 expression in chordoma tumor tissues. Two clinical trials are conducting on the therapy of osteosarcoma and myeloma using B7-H3 as a target. In conclusion, B7-H3 could be a target of bone cancers. |
| |
Keywords: | Corresponding author. B7-H3 Bone Joint Cancer |
本文献已被 ScienceDirect 等数据库收录! |
|